ORYZON realizará múltiples actividades corporativas en conferencias internacionales en marzo-abril
Oryzon Genomics will participate in several international events in March and April, including BIO-Europe Spring 2025 in Milan and the Van Lanschot Kempen Life Sciences Conference in Amsterdam, where it will hold meetings with investors and pharmaceutical companies.
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April.
Oryzon will attend the Bio-Europe Spring 2025, which will be held at the Allianz MiCo in Milan (Italy) on March 17-19, where the company will maintain meetings with investors and pharma companies
Oryzon has been invited to participate at the Van Lanschot Kempen Life Sciences çConference, which will take place in their offices located in Amsterdam (Netherlands) on April 1-3, where the company will maintain meetings with investors.